Cyclosporin was well tolerated and efficacious in the symptomatic treatment of atopic dermatitis in dogs attending two veterinary dermatology referral centres in Australia, under Australian field conditions, when administered at 5 mg/kg/day for 6 weeks.
An 8-month-old, crossbred dog, presented with a painful, swollen face. The problem was of 4 weeks duration and had not responded to antibiotics. A diagnosis of canine juvenile cellulitis was based on the clinical presentation and supportive cytological and histopathological changes. Attempts to identify canine distemper virus were not successful. Complete resolution occurred with glucocorticoid therapy. This is the first report of canine juvenile cellulitis in a dog of this age.
The purpose of this study was to determine if Cyclosporin A, given at a dose of 5 mg kg−1 per day for 42 days, negatively influenced intradermal skin test results in dogs with atopic dermatitis. Six mixed‐breed dogs of varying ages and sexes with a clinical diagnosis of atopic dermatitis were included in this study. All dogs were intradermally skin tested (IDT) with 61 allergens from varying groups, grass pollens, weed pollens, tree pollens, moulds, insects and dust mites. IDT reactions were recorded as absent, weak, moderate or strong reactions. All dogs showed several strong reactions in the initial IDT. On days 0 to 42, the dogs received 5 mg kg −1 per day of Cyclosporin A. On day 42, all dogs showed a marked reduction in pruritus. A second IDT was performed and the results of both tests compared. The χ2‐test was used to statistically analyse changes between pre‐ and post‐treatment reactions for each of the allergen groups. There were no mould reactions recorded and this group was discarded from analysis. When all reactions were used in analysis, Cyclosporin A tended to significantly reduce the number of IDT reactions. However, when only moderate and strong reactions were considered (weak reactions excluded) there were no significant differences between pre‐ and post‐treatment results for the other allergen groups. Cyclosporin A at a dose of 5 mg kg−1 per day for 42 days controlled pruritus, but did not significantly alter moderate and strong intradermal skin test reactions in the six dogs tested. This suggests that Cyclosporin A, at this dose, did not prevent mast cell degranulation.
Funded by Novartis Animal Health, Australia.
Mucocutaneous pyoderma is a disease of unknown aetiology affecting mucocutaneous skin and is responsive to antibacterial therapy. It is reported to affect the lips, nasal planum, nares, perioral skin and less commonly, the eyelids, vulva, prepuce and anus. Three cases of mucocutaneous pyoderma are presented. Two of the cases showed ulcerative lesions in the inguinal and axillary regions in addition to more typically reported lesions. Two of the dogs had concurrent atopic dermatitis and the third had clinical signs suggestive of hyper-sensitivity disease. The clinical and histopathological features, differentiation of mucocutaneous pyoderma from discoid lupus erythematosus, and long-term management of mucocutaneous pyoderma are discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.